A team-based approach that weaves together multidisciplinary care and algorithm-based medical therapy can have a big impact on getting LDL-cholesterol levels under control in patients with peripheral ...

The investigational CETP inhibitor obicetrapib—a drug initially developed to raise HDL-cholesterol levels—has passed another milestone in its quest towards approval, this time in patients with ...

NEW ORLEANS — Lowering the level of low-density lipoprotein (LDL) cholesterol to below 40 mg/dL — well beneath current poststroke guideline targets — reduced major cardiovascular events without ...

Please provide your email address to receive an email when new articles are posted on . Inclisiran is now FDA approved as monotherapy for LDL reduction. The drug is no longer required to be used on ...

Please provide your email address to receive an email when new articles are posted on . Obicetrapib conferred sustained LDL lowering for patients with HeFH already on maximally tolerated ...

ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL ®) is now recommended as an important oral non-statin therapy for ...

High cholesterol is associated with an increased risk for cardiovascular conditions like heart disease, stroke, and atherosclerosis. If your doctor has recommended lowering your cholesterol, this ...

Researchers at the Department of Advanced Biomedical Sciences at "Federico II" University in Naples report that lower plasma LDL cholesterol is associated with a higher risk of incident type 2 ...